LifeStance Health Group (NASDAQ:LFST) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of LifeStance Health Group (NASDAQ:LFST) from a hold rating to a buy rating in a research report released on Sunday morning.

A number of other equities analysts have also recently issued reports on LFST. BMO Capital Markets started coverage on shares of LifeStance Health Group in a research report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price objective on the stock. BTIG Research raised their target price on LifeStance Health Group from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. Barclays started coverage on LifeStance Health Group in a research report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price target for the company. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.00.

LifeStance Health Group Stock Up 2.1%

Shares of LifeStance Health Group stock opened at $6.95 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $8.30. The company’s 50 day moving average price is $7.03 and its 200-day moving average price is $5.95. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of -231.67 and a beta of 1.12.

Insider Activity

In related news, insider Lisa K. Miller sold 57,240 shares of LifeStance Health Group stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $6.43, for a total transaction of $368,053.20. Following the sale, the insider directly owned 261,292 shares in the company, valued at $1,680,107.56. The trade was a 17.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ann Varanakis sold 50,000 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total value of $345,000.00. Following the completion of the transaction, the insider owned 315,610 shares of the company’s stock, valued at approximately $2,177,709. This trade represents a 13.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 327,326 shares of company stock worth $2,259,317 in the last quarter. 6.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently bought and sold shares of LFST. Royal Bank of Canada lifted its holdings in shares of LifeStance Health Group by 63.4% during the first quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock valued at $468,000 after purchasing an additional 27,244 shares during the last quarter. AQR Capital Management LLC raised its stake in LifeStance Health Group by 223.0% during the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock valued at $343,000 after buying an additional 35,554 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in LifeStance Health Group by 3.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock valued at $952,000 after buying an additional 4,169 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in LifeStance Health Group by 1.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock worth $4,100,000 after acquiring an additional 11,331 shares in the last quarter. Finally, Blair William & Co. IL purchased a new stake in shares of LifeStance Health Group in the second quarter worth $70,000. Hedge funds and other institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.